Stellate Cells Aid Growth-Permissive Metabolic Reprogramming and Promote Gemcitabine Chemoresistance in Pancreatic Cancer

SIMPLE SUMMARY: The great majority, more than 90%, of patients with pancreatic ductal adenocarcinoma (PDAC) die within less than five years after detection of the disease, despite recent treatment advances. The poor prognosis is related to late diagnosis, aggressive disease progression, and tumor re...

Descripción completa

Detalles Bibliográficos
Autores principales: Amrutkar, Manoj, Gladhaug, Ivar P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913350/
https://www.ncbi.nlm.nih.gov/pubmed/33546284
http://dx.doi.org/10.3390/cancers13040601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913350/
https://www.ncbi.nlm.nih.gov/pubmed/33546284
http://dx.doi.org/10.3390/cancers13040601

Ejemplares similares